Lilly, Daiichi launch prasugrel in U.K.
Eli Lilly and Daiichi Sankyo have launched their new heart drug prasugrel (Efient) in the U.K., following its authorization by the European Medicines Agency (EMEA).

Prasugrel is indicated for patients with acute coronary syndrome, who have unstable angina or have had a heart attack. The approval of prasugrel is based upon data from several trials including TRITON-TIMI 38, a global head-to-head superiority trial involving 13,608 patients worldwide, when compared to clopidogrel (Plavix), according to the Indianapolis-based Lilly and the Tokyo-based Daiichi.

Prasugrel is the first new oral antiplatelet to be licensed in the U.K. for more than a decade.